1. P Jordan - Editorial 2. P Jordan/ P Matos (INSA, Lisbon) - BRAF mutant and MSI-type 3. Raquel Seruca/Sofia Fernandes (IPATIMUP, Porto) - PI3K as therapeutic target 4. Eric Chastre/ L Kotelevets (INSERM Paris) - targeting PTEN in CRC 5. Luis Costa/Marta Martins (Hospital S Maria, Lisbon) - Clinical response and resistance to EGFR therapy 6. Cecilia Rodrigues (F Pharmacy, Lisbon) - miRNAs as modulators of EGFR therapy 7. Jesus Garcia-Fonsillas (Madrid)- Targeting KRAS mutant CMS3 subtype by metabolic inhibitors 8. Targeting TGFb and subtype CMS4 9. Hugo Snippert/Carla Veríssimo (Utrecht, NL)- promise of patient-derived colon organoids in targeted therapy. ukryj opis